Comparative Pharmacology
Head-to-head clinical analysis: METROCREAM versus METROGEL VAGINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METROCREAM versus METROGEL VAGINAL.
METROCREAM vs METROGEL-VAGINAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
Topical, apply a thin film to affected area once or twice daily.
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Renal: 60-80% unchanged; fecal/biliary: 6-15%
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)